Methylergometrine

Methylergometrine (Methylergonovine) is an orally active 5-HT2B ligand agonist. The distribution half-life of Methylergometrine is only 1-2 min. Methylergometrine can be used as an oxytocin to treat uterine atony[1][2][3].

Product Specifications

CAS Number

[113-42-8]

Product Name Alternative

Methylergonovine; Ryegonovin (free base) ; Spametrin F (free base)

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/methylergometrine.html

Solubility

10 mM in DMSO

Smiles

[H][C@]1(C2=C[C@@H](C(N[C@H](CO)CC)=O)CN1C)CC3=CNC4=C3C2=CC=C4

Molecular Formula

C20H25N3O2

Molecular Weight

339.43

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Hajjo R, et al. Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs. J Med Chem. 2010 Nov 11;53 (21) :7573-86. |[2]Amant F, et al. Misoprostol compared with methylergometrine for the prevention of postpartum haemorrhage: a double-blind randomised trial. Br J Obstet Gynaecol. 1999 Oct;106 (10) :1066-70. |[3]Mäntylä R, et al. Plasma and tissue concentrations of methylergometrine (methylergonovine) in the rabbit. Acta Pharmacol Toxicol (Copenh) . 1980 Apr;46 (4) :245-9.